"We believe success in the refractory epilepsy program is strongly supported by recent oral CBD data in orphan pediatric epilepsies achieved by GW Pharmaceuticals (GWPH – Overweight). Furthermore, the delivery of CBD through the skin, avoiding first pass metabolism by the liver, could represent a significant advantage, in our view"